GMED Stock Overview
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
No risks detected for GMED from our risk checks.
Globus Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$64.92|
|52 Week High||US$84.23|
|52 Week Low||US$57.21|
|1 Month Change||-17.82%|
|3 Month Change||-2.01%|
|1 Year Change||-8.74%|
|3 Year Change||59.98%|
|5 Year Change||110.30%|
|Change since IPO||380.89%|
Recent News & Updates
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Globus Medical, Inc. ( NYSE:GMED ), might not be a large cap stock, but it received a lot of attention from a...
|GMED||US Medical Equipment||US Market|
Return vs Industry: GMED exceeded the US Medical Equipment industry which returned -16.2% over the past year.
Return vs Market: GMED exceeded the US Market which returned -12.9% over the past year.
|GMED Average Weekly Movement||6.4%|
|Medical Equipment Industry Average Movement||10.6%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: GMED is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: GMED's weekly volatility (6%) has been stable over the past year.
About the Company
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants.
Globus Medical Fundamentals Summary
|GMED fundamental statistics|
Is GMED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GMED income statement (TTM)|
|Cost of Revenue||US$243.36m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.40|
|Net Profit Margin||14.77%|
How did GMED perform over the long term?See historical performance and comparison
Is Globus Medical undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GMED ($64.92) is trading below our estimate of fair value ($118.55)
Significantly Below Fair Value: GMED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GMED is poor value based on its PE Ratio (46.5x) compared to the US Medical Equipment industry average (35.2x).
PE vs Market: GMED is poor value based on its PE Ratio (46.5x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: GMED is poor value based on its PEG Ratio (3.9x)
Price to Book Ratio
PB vs Industry: GMED is overvalued based on its PB Ratio (3.7x) compared to the US Medical Equipment industry average (2.4x).
How is Globus Medical forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMED's forecast earnings growth (11.9% per year) is above the savings rate (1.9%).
Earnings vs Market: GMED's earnings (11.9% per year) are forecast to grow slower than the US market (12.5% per year).
High Growth Earnings: GMED's earnings are forecast to grow, but not significantly.
Revenue vs Market: GMED's revenue (10.7% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: GMED's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMED's Return on Equity is forecast to be low in 3 years time (13.1%).
How has Globus Medical performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMED has high quality earnings.
Growing Profit Margin: GMED's current net profit margins (14.8%) are higher than last year (14.7%).
Past Earnings Growth Analysis
Earnings Trend: GMED's earnings have grown by 5.4% per year over the past 5 years.
Accelerating Growth: GMED's earnings growth over the past year (16.7%) exceeds its 5-year average (5.4% per year).
Earnings vs Industry: GMED earnings growth over the past year (16.7%) exceeded the Medical Equipment industry 14.5%.
Return on Equity
High ROE: GMED's Return on Equity (8%) is considered low.
How is Globus Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GMED's short term assets ($916.6M) exceed its short term liabilities ($141.5M).
Long Term Liabilities: GMED's short term assets ($916.6M) exceed its long term liabilities ($71.8M).
Debt to Equity History and Analysis
Debt Level: GMED is debt free.
Reducing Debt: GMED has not had any debt for past 5 years.
Debt Coverage: GMED has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMED has no debt, therefore coverage of interest payments is not a concern.
What is Globus Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMED's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GMED has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Scavilla (56 yo)
Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD1.94M) is below average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Experienced Management: GMED's management team is seasoned and experienced (14.9 years average tenure).
Experienced Board: GMED's board of directors are considered experienced (8.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Globus Medical, Inc.'s employee growth, exchange listings and data sources
- Name: Globus Medical, Inc.
- Ticker: GMED
- Exchange: NYSE
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$6.606b
- Shares outstanding: 101.75m
- Website: https://www.globusmedical.com
Number of Employees
- Globus Medical, Inc.
- 2560 General Armistead Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.